Johnson & Johnson (JNJ) News Today

Johnson & Johnson (JNJ) shares moved today on a mix of analyst actions, pipeline progress and broader market sentiment. Below are the key factors influencing the stock’s performance:

• Positive Sentiment: Morgan Stanley raised its price target on JNJ from $169 to $171 and kept an "equal weight" rating, reflecting confidence in the company’s outlook. Morgan Stanley Forecast
• Positive Sentiment: JNJ submitted a supplemental NDA to the FDA for its schizophrenia drug Caplyta based on strong relapse-prevention data, bolstering its psychiatric portfolio. Caplyta sNDA Submission
• Positive Sentiment: The company appointed a new Chief Medical Officer for its Electrophysiology business, enhancing leadership in a key MedTech segment. New CMO Appointment
• Positive Sentiment: JNJ is featured among three AI-driven medical device stocks to watch in 2025, highlighting its advances in diagnostics and surgical tech. AI-Driven Devices Article
• Neutral Sentiment: Wall Street analysts released their Q2 estimates for JNJ’s top- and bottom-line metrics ahead of its July 16 earnings report. Q2 Outlook
• Neutral Sentiment: Benzinga detailed recent forecast adjustments from the most accurate analysts as JNJ gears up for its Q2 print. Forecast Changes
• Neutral Sentiment: Eight analyst projections on JNJ’s long-term growth—covering sales, R&D spend and margins—were published by Benzinga. Analyst Projections
• Neutral Sentiment: JNJ was repeatedly cited in dividend-stock roundups, underscoring its appeal for income-seeking investors:
  • Top Healthcare Dividend Picks
  • Dividend Stocks to Double Up
  • Turn $5K into $300K with JNJ
• Negative Sentiment: Pre-market declines were driven by President Trump’s tariff threats against Canada, creating headwinds for healthcare and industrial names. Tariff Threats

Overall, positive pipeline developments and analyst upgrades provided upward momentum for JNJ shares, while macro trade-related concerns applied some downward pressure.